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a b s t r a c t
Background: Sustainedantibody levels are ahallmarkof immunity againstmanypathogens, and induction
of long-term durable antibody titers is an essential feature of effective vaccines. Heterologous prime-
boost approaches with vectors are optimal strategies to improve a broad and prolonged immunogenicity
of malaria vaccines.
Results: In this study, we demonstrate that the heterologous prime-boost regimen Ad35-CS/BCG-CS
induces stronger immune responses by enhancing type 1 cellular producing-cells with high levels of







ogous BCG-CS/CSp prime-boost regimen. Moreover, the heterologous prime-boost regimen elicits the
highest level of LLPC-mediated immune responses.
Conclusion: The increased IFN--producing cell responses induced by the combination of Ad35-CS/BCG-
CS and sustained type 1 antibody proﬁle together with high levels of LLPCs may be essential for the
development of long-term protective immunity against liver-stage parasites.. Introduction
Although a successful eradication of certain infectious diseases
uch as smallpox has been realized, vaccination strategies against
uman pathogenic parasites remain a fundamental challenge for
iomedical research [1]. Long-lasting protective antibody produc-
ion is one of the hallmarks of effective vaccination and is an
mportant feature of immunological memory [2].
The clinically silent liver stage of Plasmodium infection epito-
izes an attractive target for antimalarial vaccine development3,4]. However, despite decade long endeavors, no antimalarial vac-
ines have been licensed today. Nevertheless, promising results are
merging despite the fact that the leading pre-erythrocytic subunit
∗ Corresponding authors at: Department of Immunology, TheWenner-Gren Insti-
ute Stockholm University, Svante Arrhenius väg 20C, House F Floor 5, SE-106 91,
tockholm, Sweden. Tel.: +46 8164170.
E-mail addresses: charles.arama@wgi.su.se, charama@icermali.org (C. Arama),
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vaccine candidate (RTS,S) has proven to be only partially protective
in clinical trials [5].
In theprevious study,wehave shown that a recombinant (r) BCG
expressing the Plasmodium falciparum circumsporozoite protein
(BCG-CS) induced activation and priming of CSp-speciﬁc immu-
nity in BALB/c mice [6]. A prime-boost regimen consisting of this
BCG-CS combinedwith adenovector 35 (Ad35) expressing the same
antigen (Ad35-CS) is utilized in this work. Based on evidences in
literature we conclude that a reasonable strategy to induce broad
and prolonged immune response against malaria infection may be
realizedbyprimingwith recombinant virus andboostingwith rBCG
[7–9]. Therefore, a rBCG provides an option that can ﬁt within the
existing World Health Organization (WHO) expanded program of
immunization (EPI) considering that BCG is being given at birth.
Since amajor concern is, howto induceprotective cell-mediated
immunity (CMI) particularly IFN--producing CD8+ T cells, which
have been shown to provide long-term immunity to malaria [10].
These cells are essential in combatingparasitic infections, including
malaria. Due to intracellular expression of the CSp insert in the
rAd35 genome and the intracellular residence of BCG expressing


























































BALB/c mice Prime week 0 Boost week 4
Group 1 (8 mice) BCG-CS, 106 CFU BCG-CS, 106 CFU
Group  2 (8 mice) BCG-CS, 106 CFU CSp, 5 gC. Arama et al. / Vacc
he same antigen, we propose that BCG-CS is likely an efﬁcient route
f antigen delivery. Moreover, the expressed CSp is expected to be
rocessed in the cytosolic pathway and presented efﬁciently with
lass I major histocompatibility (MHC) molecules [11,12].
During  parasitic infection, the immune response mediated by
D4+ and CD8+ T cells is crucial for effective protection, also against
alaria [13]. The induction of antigen-speciﬁc long-lived immune
esponses accompanied by an expansion of CD4+ and CD8+ T cells
lays a pivotal role in malaria vaccine development. To accomplish
his, it is therefore important to investigate optimal prime-boost
trategies.
Sustained antibody levels are a hallmark of immunity against
any pathogens, and induction of long-term durable antibody
iters is an essential feature of effective vaccines. In the con-
ext of humoral immunity, the ability of a vaccine to confer this
ong-term immunity depends on both memory B cells and long-
ived plasma cells (LLPCs) [14]. Numerous mechanisms have been
roposed whereby persistent antibody production can be main-
ained, such as low-grade chronic infection, repeated antigenic
xposure, antigen–antibody complexes, idiotypic networks and
ross-reactivity to self or environmental antigens [2]. However,
ore recent investigations have shown that antibody titers can
ersist despite the lack of antigen exposure, for decades. In addi-
ion, sustained antibody titers after immunization in humans do
ot appear to require memory B-cell activation [15]. The source
f this long-term antigen-speciﬁc antibody has been identiﬁed as
one marrow (BM)-resident nonproliferating plasma cell subsets
alled LLPCs [16,17]. We  hypothesize therefore that the long-term
esponse conferred against P. falciparum CSp in the present study is
ue to the capacity of the heterologous prime-boost, Ad35-CS/BCG-
S, to generate markedly enhanced LLPC responses. To this end, we
valuated the quantity and quality of cellular immune responses
nduced by a heterologous prime-boost regimen using Ad35-CS
ollowed by BCG-CS to induce CSp-speciﬁc memory immunity.
In  this study, we demonstrate that the heterologous prime-
oost regimen Ad35-CS/BCG-CS induces stronger immune
esponses by enhancing a type 1 cellular immune response with
igh levels of CSp-speciﬁc IFN- producing-cells and cytophilic
gG2a antibodies as compared to the homologous BCG-CS and
he heterologous prime-boost BCG-CS/CSp regimen. Moreover,
e show that the heterologous prime-boost regimen elicits the
ighest level of LLPC-mediated immune responses.
. Materials and methods
.1.  Animals and immunization procedures
The immunization procedures were performed according to the
wedish Animal Act and were approved by the Swedish Animal
are and Ethical Review committee. Six to eight week-old female
ALB/c mice were obtained from NOVA-SCB (Sollentuna, Sweden)
nd were housed in speciﬁc pathogen-free conditions in the animal
acility at Stockholm University. The BCG-CS was formulated in PBS
ith 0.05% Tween 80 and administered subcutaneously (s.c.) at the
orsal neck at a dose of 106 colony forming units (CFU) in a total
olume of 100 l. The Ad35-CS was formulated in PBS and was
iven intramuscularly (i.m.) at the gastrocnemius muscle at a dose
f 109 viral particles (vp) in a total volume of 50 l (i.e., 25 l in each
eg). Boosting immunizations were given 4-week post-priming in
he same procedure as above in all cases..2. Recombinant BCG-CS and AD35-CS vaccine constructs
The  BCG-CS and Ad35-CS constructs, expressing CSp, have been
escribed previously [6,18].Group  3 (8 mice) Ad35-CS, 109 vp BCG-CS, 106 CFU
Group  4 (4 mice) Ad35-CS, 109 vp Ad35-CS, 109 vp
2.3. Immunization design and dosage
The immunization design and the dosage of the different vac-
cines are summarized in Table 1.
2.4. Peptides and proteins
Speciﬁc  responses to P. falciparum CSp were measured by stim-
ulating splenocytes and LLPCs with peptides deduced from the CSp
antigen; namely, the C-terminal (C-CSp, PfCS282-383), N-terminal
(N-CSp, PfCS22-110) and immunodominant CD8+ T cell epitope
(IDE-CSp, PfCS-NYDNAGTNL). The synthesis and immunological
characterizations of those peptides have been reported in details
elsewhere [19,20]. The rCSp was provided by Crucell (Leiden, The
Netherlands) and has been described elsewhere [12].
2.5.  Isolation of splenocytes and long-lived plasma cells
Spleen-cell suspensions were prepared by teasing the organ
with sterile forceps followed by passing through 27G needles sev-
eral times, and then centrifugation. Bone marrow (BM) cells were
collected from the BM of femurs and tibias by ﬂushing them
with RPMI. Red blood cells (RBC) were removed by resuspend-
ing cells in ACK RBC-lysis buffer (0.15 M NH4Cl, 10 mM KHCO3,
0.1 mM  Na2EDTA in dH2O and adjusted pH to 7.2–7.4 with 1 M HCl;
all compounds were purchased from Sigma–Aldrich, Steinheim,
Germany) for 5 min  before adding excess of RPMI. Splenocytes and
LLPCs were puriﬁed by centrifugation and resuspended in com-
plete RPMI (RPMI 1640, 10% FCS, 100 IU/ml penicillin, 100 mg/ml
streptomycin, 4 mM l-glutamine).
2.6. CSp-speciﬁc antibody detection in the serum of immunized
mice
CS-speciﬁc antibody responses were assessed by ELISA. Ninety-
six-well microtiter plates (Costar 96-well HB half Area plate,
Corning Inc, NY) were coated overnight with 2 g/ml CSp in 0.05 M
carbonate buffer (pH 9.6) at room temperature. Plates were washed
three times with PBS/0.05% Tween 20 and a 1:400-dilution of indi-
vidual serum samples were added to corresponding wells and a
serial dilution of 2-fold with PBS/0.05% Tween 20. Plates were incu-
bated for 2 h at room temperature and were washed three times
and incubated with alkaline phosphatase-labeled anti-mouse IgG
(Southern Biotech, Birmingham, AL, USA). For detection of IgG sub-
classes, samples were incubated with alkaline phosphatase-labeled
anti-mouse IgG1 or IgG2a antibodies (Southern Biotech, Birming-
ham, AL). The enzyme/substrate reaction was developed using
p-nitrophenyl phosphate (Sigma–Aldrich, Steinheim, Germany).
Optical density was measured at 405 nm by using a V max  ELISA
reader (Molecular Devices Instruments).
2.7. CSp-speciﬁc T-cell responses in splenocytes of immunized
miceCSp-speciﬁc cellular immune responses in vaccinated mice
were measured using an IFN- ELISPOT assay. The spleno-
cytes from each group of mice were stimulated with a pool of

























































Fig. 1. Effect of heterologous prime-boost Ad-35-CS/BCG-CS regimen on anti-
body  responses against CSp. Immunogenicity of heterologous prime-boost regimen,
comprising BCG-CS and Ad35-CS, was analyzed. BALB/c mice (4 per group) were
immunized as indicated in the graphs. Two weeks after booster immunization,
CSp-speciﬁc  humoral immune responses were assessed by evaluating CSp-speciﬁc
IgG  (A), IgG1 (B) and IgG2a responses (C) using ELISA. Circle and triangle legends
show  results from each individual mouse and the horizontal bars represent mean042 C.  Arama et al. / Vac
. falciparum CSp peptides consisting of C-CSp (PfCS282-383),
-CSp (PfCS22-110) and IDE-CSp (PfCS-NYDNAGTNL). Multi-
creen plates (96-wells) were pre-coated with anti-mouse IFN-
Mabtech, Nacka, Sweden) and blocked with complete medium
RPMI 1640 containing 10% FCS supplemented with 1 mM l-
lutamine and penicillin–streptomycin) for 30 min. After removing
he medium, splenocytes from individual mice at a density of 105
ells/well were stimulated with a pool of CSp peptides at a concen-
ration of 5 g/well for 48 h at 37 ◦C 5% CO2. Following incubation,
lates were washed ﬁve times with PBS and were then incubated
ith 1 g/ml of biotinylated anti-mouse antibodies (Mabtech) in
BS containing 0.5% FCS for 2 h at room temperature. After wash-
ng ﬁve times with PBS to remove free biotinylated anti-mouse
ntibodies, plates were incubated for 2 h with detection anti-
odies conjugated to streptavidin–alkaline phosphatase at 1:1000
ilutions in the same buffer as above. The enzyme reaction was
eveloped with nitroblue tetrazolium bromo-4-chloro-3-indolyl-
hosphate  chromogen substrate (Mabtech). The spot-forming units
SFU) per 105 cells were counted using a dissection microscope
Carl Zeiss, Stemi 2000-C).
.8.  Detection of CSp-speciﬁc LLPCs in BM of immunized mice
Multiscreen HTS-IP Filter Plates (96-wells, Millipore) were pre-
etted with 70% ethanol for 2 min, washed ﬁve times with PBS and
oated with 5 g/ml of CSp in PBS overnight at 4 ◦C. Plates were
locked for 2 h at room temperature with complete medium. BM
ells (105 cells per well) from the immunized mice were seeded
n duplicates and stimulated individually with the C-CSp, N-CSp
r IDE-CSp. Plates were incubated for 12 h at 37 ◦C, 5% CO2 and
5% humidity. After the incubation period plates were washed ﬁve
imes with PBS and incubated for 2 h at room temperature with
RP-conjugated goat anti-mouse IgG (1:1000; Southern Biotech)
n PBS, 5% FCS. After washing with PBS ﬁve times, the reaction
as developed using a Vectastain 3-amino-9-ethylcarbazole (AEC)
ubstrate kit (Vector laboratories, Burlingame, CA) according to
anufacturer’s instructions. The reactions were stopped by wash-
ng plates with deionized water. Plates were dried in the dark and
pots were counted using a dissection microscope (Carl Zeiss, Stemi
000-C).
.9. Statistical analysis
Data  were analyzed using GraphPad Prism Version 5 (Graphpad
oftware, Inc., San Diego, CA). The nonparametric Kruskal–Wallis
est was used for the comparison of means in different groups. For
ll tests, p ≤ 0.05 was considered signiﬁcant.
.  Results
.1. Immunogenicity of a heterologous prime-boost regimen
The  combination of Ad35-CS and BCG-CS in a heterolo-
ous prime-boost regimen resulted in high-levels of CSp-speciﬁc
gG responses (Fig. 1). Moreover, antibody responses exhibited
igher IgG2a (Th1-type responses) when comparing heterologous
rime-boost Ad35-CS/BCG-CS to homologous prime-boost BCG-
S/BCG-CS immunizations (Fig. 1). Among the three CSp peptides
ested (C-CSp, N-CSp and CSp-IDE), the response to C-CSp was  syn-
rgistic and induced stronger IgG2a response in the group primed
ith Ad35-CS and boosted with BCG-CS (Fig. 2). We  next investi-
ated whether the Ad35-CS/BCG-CS prime-boost regimen results
n a Th1 immune response, which is predominantly effective in
efense against intracellular infection (virus and parasite infec-
ions). A group of mice were primed with BCG-CS and boosted
ith CSp (heterologous prime-boost BCG-CS/CSp). Another groupOD values of two  independent experiments for each group. Statistically signiﬁcant
differences  are shown by asterisks (*p < 0.05, **p < 0.01).
of mice were primed with Ad35-CS and boosted with BCG-CS (het-
erologous prime-boost Ad35-CS/BCG-CS). A control group of mice
received priming immunization with BCG-CS, followed by BCG-CS
boosting (homologous prime-boost BCG-CS/BCG-CS). Two  weeks
after the ﬁnal boost immunization, mice receiving the heterolo-
gous prime-boost regimen, Ad35-CS/BCG-CS, showed signiﬁcantly
higher levels of IFN- responses upon re-stimulation with the pool
of CSp peptides than mice receiving the BCG-CS/CSp prime-boost
regimen (p value <0.05; Fig. 3A), and also a higher response than
the control group (Fig. 3A). The numbers of CSp-speciﬁc IFN--
producing cells, as measured by Elispot assays, were signiﬁcantly
higher in the group of mice that had received the heterologous
C. Arama et al. / Vaccine 30 (2012) 4040– 4045 4043
Fig. 2. Effect of heterologous prime-boost Ad-35-CS/BCG-CS regimen on antibody responses against CSp peptides. Immunogenicity of heterologous prime-boost regimen,
comprising BCG-CS and Ad35-CS, was analyzed. BALB/c mice (4 per group) were immu
N-CSp- and IDE-CSp-speciﬁc humoral immune responses were assessed by evaluating IgG
independent experiments for BCG-CS/BCG-CS and Ad35-CS/BCG-CS groups respectively.
Fig. 3. CSp-speciﬁc IFN- production  by splenocytes. Splenocytes isolated 2 weeks
after the last immunization were cultured individually and re-stimulated with a
pool of CSp peptides: C-CSp, N-CSp and IDE-CSp. IFN- responses were measured
after  72 h of stimulation. The individual mouse means of triplicates are presented
in circles and triangles and horizontal bar represents group mean value (pg/ml)
(A).  CSp-speciﬁc immune responses of splenocytes were assessed by IFN- ELISPOT
assay  (B). Bars represent means of spot-forming units (SFU) and circles and triangles
show SFUs for each individual mouse. Signiﬁcant differences are shown by asterisks
(*p < 0.05, **p < 0.01). Data represent two independent experiments.nized as indicated in the graphs. Two weeks after booster immunization, C-CSp-,
1 and IgG2a responses using ELISA. (a and b) Shows (bars) mean OD  values of two
prime-boost regimen Ad35-CS/BCG-CS (p value <0.05; Fig. 3B) com-
pared to the control group.
3.2.  Heterologous prime-boost regimen induces
antibody-secreting long-lived plasma cells responses
To investigate whether heterologous prime-boosting enhances
CSp-speciﬁc responses, LLPCs were isolated from BM and stimu-
lated for 48 h with three different peptides generated from the
P. falciparum CSp, namely C-CSp, N-CSp and CSp-IDE. The ability
of LLPCs to secret IgG upon stimulation with the peptides was
evaluated by counting spots in ELISPOT. The results are presented
as CSp-speciﬁc IgG-secreting LLPCs per 106 BM cells (Fig. 4A–C).
We found that the heterologous prime-boost Ad35Ad35-CS/BCG-
CS induced the highest number of CSp-speciﬁc IgG-secreting LLPCs.
Among the peptides, the LLPC responses to the C-terminus peptide
resulted in the highest spot density (Fig. 4A). These results suggest
the higher boosting effect of BCG-CS as compared to Ad35-CS, and
emphasize the importance of proper priming.
4. Discussion
CSp-based vaccines are yet to be proven sufﬁciently efﬁcacious
for the implementation into human vaccination practice. Efforts to
identify strategies of enhancing immune responses of CSp-based
vaccination have received a lot of interest and various delivery
systems have been emerging. The key strength of this concept is
that a greater level of immunity is established by heterologous
prime-boost than can be attained by a single vaccine adminis-
tration or homologous boost strategies [21,22]. In this work, we
explored the impact of heterologous prime-boost of a P. falciparum
CSp-based vaccine using two different live recombinant vectors
systems, rBCG and Ad35. Such approaches are identiﬁed as heterol-
ogous prime-boost strategies referring to the utilization of different
vaccines for priming and boosting to improve the immunogenic-
ity of vaccines. Enhancing the immunogenicity of CSp, the leading
malaria preerythrocytic vaccine candidate, will be a very important
cornerstone toward controlling or eradicating malaria. Although
CD8+ T effector memory cells are required for protection against
liver-stage malaria [23], prolonged survival of a subset of plasma
cells (PCs) in BM has been implicated as a key component of
long-term humoral immunity [2,24]. However, the intrinsic char-
acteristics of the PC subsets, the basis of their longevity, and their
actual contribution to durable antibody titers are incompletely
4044 C.  Arama et al. / Vaccine 30
Fig. 4. Effect of heterologous prime-boost vaccination comprised of the BCG-CS and
Ad35-CS on CSp-speciﬁc antibody-secreting long-lived plasma cells. The number of
antigen-speciﬁc LLPCs present in BM was enumerated 4 weeks after last immu-
nization  of the mice. Speciﬁc antibodies to C-CSp- (A), N-CSp- (B), and IDE-CSp-
(C)  secreting LLPCs are shown for each individual mouse (circles and triangles) as
well as group mean value (horizontal bar). Asterisks denote statistical signiﬁcance
(*p  < 0.05, **p < 0.01). Data are representing two independent experiments. (2012) 4040– 4045
understood. In this study, we employed two  approaches (i.e.,
use of two  delivery systems in heterologous prime-boost admin-
istration) to enhance the immunogenicity of CSp in BALB/c
mice and evaluated the outcome. We  have demonstrated that
sequential immunization with different delivery systems, the
so-called heterologous prime-boost regimen Ad35-CS/BCG-CS,
induced signiﬁcantly stronger immune responses as compared to
the homologous immunization. This strategy induced in BALB/c
mice a type 1 cellular immune response with high levels of CSp-
speciﬁc IFN--producing cells and cytophilic IgG2a antibodies as
well as induced the highest numbers of LLPCs.
Major obstacles in the development of a vaccination regimen
against malaria have traditionally been the lack of immunogenicity
of the identiﬁed candidate antigens and formulations. It has been
suggested that protection in RTS,S-vaccinated children increases
when antibody titers against CSp are above the threshold of
18–40 EU/mL. However, RTS,S/AS01E and other RTS,S formulations
are still capable of inducing those titers in all vaccinated children
despite being partially protective [25]. One way to improve the
immunogenicity of antigen is to use different recombinant vaccine
platforms such as vectors for antigen delivery [3,26]. Recombi-
nant adenovectors and rBCG are invaluable option among the
different vectors since it has been shown that they exhibit efﬁ-
cient adjuvant effects, to enhance immunogenicity and to induce
potent memory T- and B-cell responses [27,28]. Interestingly, prim-
ing with Ad35-CS and boosting with BCG-CS yielded not only
profound CMI  but also potent humoral immunity mediated by
murine IgG2a cytophilic antibodies, suggesting that this combi-
nation might be efﬁcient in inducing protective immunity. This
result corroborates previous studies showing that priming with
Ad35-CS vaccine followed by RTS,S/AS01B boosting signiﬁcantly
improves immunogenicity to P. falciparum CSp [29]. Furthermore,
the effect of adenoviral priming was  consistent in the other mouse
strains and with other antigens such as the P. falciparum mero-
zoite surface protein (MSP)–1 [30]. A recent ﬁnding from human
clinical trial has shown that priming with the recombinant simian
adenovirus ChAd63 encoding the preerythrocytic insert multiple
epitope thrombospondin-related adhesion protein (ME-TRAP;) and
giving a booster immunization 8 weeks later with a modiﬁed vac-
cinia virus Ankara (MVA) ME-TRAP induced high levels of TRAP
antigen-speciﬁc CD8+ and CD4+ T cells [31].
IFN-  plays a central mediator role in cellular responses and has
been show to be crucial against intracellular protozoan parasites
such as Plasmodium [32,33]. It is noteworthy to mention that IFN-
responses to both liver- and blood-stage antigens have been pos-
itively correlated with protection [34]. In the same line, we found
that the heterologous prime-boost Ad35-CS/BCG-CS induced sig-
niﬁcantly higher numbers of CSp-speciﬁc IFN--producing cells,
indicating the induction of a type 1 T-cell response.
The heterologous prime-boost administration also elicited the
highest levels of CSp-speciﬁc IgG and in particular IgG2a. This
ﬁnding has great implication for CSp-speciﬁc antibody responses,
which might confer protection because the IgG response in the cur-
rent heterologous prime-boost administration was  mainly induced
against the C-terminal region of CSp domain. The fact that the anti-
body response was  stronger against C-CSp implies that epitopes
responsible CSp-speciﬁc antibody responses are located in the C-
terminal domains of the protein. Prolonged survival of a subset
of PCs in BM has been implicated as the key component of the
long-term maintenance of antibody titers [35]. In this study, het-
erologous prime-boost administration was also the most efﬁcient
combination in terms of generating long-lived antibody responses;
as shown by the induction of higher numbers of CSp-speciﬁc
LLPCs upon restimulation with C-CSp. The effect of Ad35-CS/BCG-
CS combination is of particular importance as LLPCs are thought



















































[C. Arama et al. / Vacc
linical malaria in endemic areas [36]. Furthermore, a recent study
as shown that a GMZ2 vaccine, a fusion protein consisting of the
-terminal portion of the glutamate rich protein (GLURP) fused to
 C-terminal fragment of merozoite surface protein 3 (MSP3) plus
he synthetic TLR4 agonist glucopyranosyl lipid A (GLA), elicits the
ighest number of LLPCs secreting cells speciﬁc for both the GMZ2
usion protein and its two components [14].
In our current study, we tried to achieve simultaneous B- and T-
ell responses against P. falciparum CSp. Heterologous prime-boost
mmunization regimens including vaccination of Ad35-CS followed
y BCG expressing the P. falciparum CSp, could be one of the best
pproaches. The sporozoite challenge experiments are underway
o deﬁne the protective efﬁcacy of this prime-boost protocol.
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